SE8904407L - MEDICATION FOR TREATMENT OF HEART FAILURE - Google Patents

MEDICATION FOR TREATMENT OF HEART FAILURE

Info

Publication number
SE8904407L
SE8904407L SE8904407A SE8904407A SE8904407L SE 8904407 L SE8904407 L SE 8904407L SE 8904407 A SE8904407 A SE 8904407A SE 8904407 A SE8904407 A SE 8904407A SE 8904407 L SE8904407 L SE 8904407L
Authority
SE
Sweden
Prior art keywords
heart failure
medication
treatment
anp
inhibitors
Prior art date
Application number
SE8904407A
Other languages
Swedish (sv)
Other versions
SE8904407D0 (en
Inventor
Qingpingfeng
Thomashedner
Original Assignee
Qingpingfeng
Thomashedner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qingpingfeng, Thomashedner filed Critical Qingpingfeng
Priority to SE8904407A priority Critical patent/SE8904407L/en
Publication of SE8904407D0 publication Critical patent/SE8904407D0/en
Priority to EP91902229A priority patent/EP0510052A1/en
Priority to PCT/SE1990/000886 priority patent/WO1991009627A1/en
Priority to JP91502498A priority patent/JPH05506640A/en
Publication of SE8904407L publication Critical patent/SE8904407L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a combination of substances, firstly from the group of alpha -2-adrenergic agonists or other inhibitors of the sympathetic nervous system, and secondly from the group of natriuretic peptides (ANP, BNP, their pharmacologically active analogues, ANP C-receptor ligands, or inhibitors of degradation), this combination exhibiting a therapeutic diuretic and natriuretic effect in heart failure, not achievable with any substance from only one of the groups of substances.
SE8904407A 1989-12-29 1989-12-29 MEDICATION FOR TREATMENT OF HEART FAILURE SE8904407L (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
SE8904407A SE8904407L (en) 1989-12-29 1989-12-29 MEDICATION FOR TREATMENT OF HEART FAILURE
EP91902229A EP0510052A1 (en) 1989-12-29 1990-12-28 Medicament for treatment of heart failure
PCT/SE1990/000886 WO1991009627A1 (en) 1989-12-29 1990-12-28 Medicament for treatment of heart failure
JP91502498A JPH05506640A (en) 1989-12-29 1990-12-28 Medications for treating heart failure

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8904407A SE8904407L (en) 1989-12-29 1989-12-29 MEDICATION FOR TREATMENT OF HEART FAILURE

Publications (2)

Publication Number Publication Date
SE8904407D0 SE8904407D0 (en) 1989-12-29
SE8904407L true SE8904407L (en) 1991-06-30

Family

ID=20377906

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8904407A SE8904407L (en) 1989-12-29 1989-12-29 MEDICATION FOR TREATMENT OF HEART FAILURE

Country Status (4)

Country Link
EP (1) EP0510052A1 (en)
JP (1) JPH05506640A (en)
SE (1) SE8904407L (en)
WO (1) WO1991009627A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6028055A (en) * 1996-10-22 2000-02-22 Genetech, Inc. Receptor selective BNP
US7524635B2 (en) 2003-04-17 2009-04-28 Biosite Incorporated Methods and compositions for measuring natriuretic peptides and uses thereof
US7632647B2 (en) * 2001-04-13 2009-12-15 Biosite Incorporated Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes
US6461828B1 (en) 2001-09-04 2002-10-08 Syn X Pharma Conjunctive analysis of biological marker expression for diagnosing organ failure
MXPA03004105A (en) 2002-05-14 2004-10-15 Hoffmann La Roche Making a prognosis in cases of cardiac disease using a combination of markers.
PL377813A1 (en) 2002-11-26 2006-02-20 Biocon Limited Modified naturetic compounds, conjugates, and uses thereof

Also Published As

Publication number Publication date
EP0510052A1 (en) 1992-10-28
SE8904407D0 (en) 1989-12-29
WO1991009627A1 (en) 1991-07-11
JPH05506640A (en) 1993-09-30

Similar Documents

Publication Publication Date Title
DE3868037D1 (en) PHARMACEUTICAL COMPOSITION WITH DELAYED DELIVERY OF ACTIVE SUBSTANCE.
DE58904179D1 (en) SEPTUM FOR IMPLANTABLE DEVICES FOR DELIVERING ACTIVE SUBSTANCES.
DE68910159D1 (en) Dosage form for administration in human medicine.
DE3750619D1 (en) Drug delivery system.
DE3769707D1 (en) THERAPEUTIC SYSTEM WITH REGULATED DELIVERY OF ACTIVE SUBSTANCES.
DE68910867D1 (en) Matrix for the transdermal delivery of drugs.
PT693924E (en) PROCESSES FOR THE ADMINISTRATION (IN VIVO) OF BIOLOGICAL AND COMPOSITION SUBSTANCES USED IN THESE PROCESSES
DE3681570D1 (en) MEDICAL DEVICE FOR THE PULSATILE TRANSDERMAL ADMINISTRATION OF BIOLOGICALLY ACTIVE SUBSTANCES.
ATE108680T1 (en) THERAPEUTIC SYSTEM FOR DELAYED AND GOVERNED TRANSDERMAL OR TRANSMUCOSAL ADMINISTRATION OF ACTIVE INGREDIENTS (II).
DK618186A (en) ACTIVE SUBSTANCE ADMINISTRATION SYSTEM
DE3586713D1 (en) DEVICE FOR THE CONTROLLED DELIVERY OF MEDICINAL ACTIVE SUBSTANCES.
BR9106977A (en) METHOD TO SUPPRESS AUTOIMMUNE DESTRUCTION OF PANCREATIC BETA CELUIAS, PHARMACEUTICAL FORMULATION, PROPHYLAXIS METHOD, METHOD TO PREVENT THE SURGE OF TYPE 1 DIABETES AND METHOD FOR TREATING A MAMMAL
DE69533112D1 (en) USE OF FLAVOLIGNANES FOR THE PRODUCTION OF MEDICINES WITH ANTIPROLIFERATIVE ACTIVITY IN UTERUS, BREAST, EGGS
NO990916D0 (en) Use of GLP-1 or analogues in the treatment of myocardial infarction
DE69621918D1 (en) DRUGS FOR TREATING AUTOIMMUNE DISEASES WITH INTERFERON TAU
NO882897L (en) PHARMACEUTICAL DELIVERY SYSTEM.
DE3682229D1 (en) PHARMACEUTICAL PREPARATIONS USED FOR STIMULATING TREATMENT SECRETION.
GR3019171T3 (en) System for delivering drug with enhanced bioacceptability.
DE69839423D1 (en) PROCESS FOR PREVENTION OF GASTRITIS USING AMYLIN OR AMYLIN AGONISTS
SE8904407L (en) MEDICATION FOR TREATMENT OF HEART FAILURE
PT750515E (en) LOW MOLECULAR WEIGHT HYALURONIC ACID CONTAINING A PEPTIDE OR A PROTEIN
DK79889D0 (en) MULTI-LAYER PLASTS FOR TRANSDERMAL PHARMACEUTICAL ADMINISTRATION
DE3773893D1 (en) SYNERGISTIC COMBINATION OF AZELASTINE AND THEOPHYLLIN OR AZELASTINE AND BETA MIMETIC.
DK403384D0 (en) ENTERALLY EFFECTIVE, BIOLOGICALLY ACTIVE PEPTIDE OR PROTEIN AGENTS AND PROCEDURES FOR PRODUCING THEREOF
DE3884309D1 (en) Transdermal delivery system for procaterol.

Legal Events

Date Code Title Description
NAV Patent application has lapsed

Ref document number: 8904407-7

Effective date: 19930701